Compile Data Set for Download or QSAR
Report error Found 17 Enz. Inhib. hit(s) with all data for entry = 8217
TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237087(US9388198, 13)
Affinity DataIC50: 3.40nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237088(US9388198, 14)
Affinity DataIC50: 6.30nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237076(US9388198, 2)
Affinity DataIC50: 28nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237089(US9388198, 15)
Affinity DataIC50: 33nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237086(US9388198, 12)
Affinity DataIC50: 41nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237085(US9388198, 11)
Affinity DataIC50: 60nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237084(US9388198, 10)
Affinity DataIC50: 74nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237079(US9388198, 5)
Affinity DataIC50: 272nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237078(US9388198, 4)
Affinity DataIC50: 332nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237082(US9388198, 8)
Affinity DataIC50: 340nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237090(US9388198, 16 | US9388198, 17)
Affinity DataIC50: 348nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237081(US9388198, 7)
Affinity DataIC50: 478nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237090(US9388198, 16 | US9388198, 17)
Affinity DataIC50: 543nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237075(US9388198, 1)
Affinity DataIC50: 818nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237080(US9388198, 6)
Affinity DataIC50: 1.37E+3nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237083(US9388198, 9)
Affinity DataIC50: 1.43E+3nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM237077(US9388198, 3)
Affinity DataIC50: 2.04E+3nMT: 2°CAssay Description:Cells were grown to confluency in adherent culture at 37° C. in a humidified 5% CO2 incubator (split 1/5 every 3-4 days with DMEM, 10% FCS, 1% Pe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
US Patent